A novel combination of pozelimab and cemdisiran appears to be better than Ultomiris (ravulizumab) at controlling intravascular hemolysis — the rupture of red blood cells inside blood vessels — in adults with paroxysmal nocturnal hemoglobinuria (PNH), showing promise as a potential treatment for the rare acquired disease. That’s…
Read more
I recently wrote a column titled “How I’m reflecting on 2024 while preparing for the new year.” In it, I shared that I want to work out more consistently in 2025, exercising three or four days a week. That made me think about my answer to the question, “How…
Patients with paroxysmal nocturnal hemoglobinuria (PNH) in 53 countries with limited access to life-saving treatments will be able to receive treatment with Fabhalta (iptacopan). The Max Foundation, a global nonprofit organization, and Novartis are expanding their collaboration to address the unmet needs of patients across Sub-Saharan…
The time has come for me to bid farewell to readers of my column. I took some time off from writing to reflect on my purpose, spend time with my growing family, and focus on my health. I can’t thank Bionews, the parent company of this website, enough for…
Get regular updates delivered to your inbox.
